0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive Disorder

Gerard Sanacora, MD, PhD1
[+] Author Affiliations
1Department of Psychiatry, Yale University, New Haven, Connecticut
JAMA Psychiatry. 2016;73(7):651-652. doi:10.1001/jamapsychiatry.2016.0780.
Text Size: A A A
Published online

Extract

Despite the tremendous personal agony and societal burden associated with major depressive disorder (MDD), we have not been able to significantly improve the effectiveness of our treatments for more than 5 decades. Large real-world studies, such as the Sequenced Treatment Alternatives to Relieve Depression (STAR*D),1 have presented us with humbling data on the relatively low rates of sustained remission associated with our current armamentarium of therapeutic options and have led many in the field to suggest that future targets for antidepressant drug development should be based on a deeper understanding of the pathophysiologic mechanisms underlying the disorder and not the “me-too” approach that has dominated the field. Accumulating evidence now suggests that dysregulation of the glutamatergic neurotransmitter system and its effects on neuroplasticity may play a critical role in the pathophysiology of depression and may thus provide a viable target for future drug development.2

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,187 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Evidence to Support the Update

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Evidence Summary and Review 2

brightcove.createExperiences();